000739 Apeloa Pharmaceutical
- 16.32
- -0.34-2.04%
About Apeloa Pharmaceutical Company
The company was founded in 1989. It is a pharmaceutical industry development platform for the famous private enterprise Hengdian Group, and a company listed on the main board of the Shenzhen Stock Exchange. The company's API business has accumulated a large number of technical achievements and human resources, and has taken the lead and continues to invest heavily in environmental protection management, technological transformation, and product development in the Chinese API industry. It has formed a strong competitive advantage in terms of cost, quality, EHS and technology, and has become a leading domestic specialty ingredient enterprise. The main business covers R&D, production and sales of API intermediates, innovative drug R&D and production services (CDMO), formulations, etc., as well as import and export trade business. The main products include levetiracetam tablets, ufenmex capsules, cefixime series, amoxicillin and clavulanate potassium capsules, levofloxacin tablets, metoprolol succinate sustained-release tablets, fucloxacillin sodium for injection, and ceftazidime for injections (cooperation). Ranked 38th in the “2022 China Pharmaceutical Industry Top 100 Enterprises”. It was awarded the National Development and Reform Commission's “Advanced Manufacturing and Modern Service Industry Integrated Development Pilot Project” and the honorary title of “Green Factory” at the national level; won the “China Top 100 High-Growth Enterprise Award”; selected as an “Eagle Action” nurturing enterprise in Zhejiang Province; “2023 Top 20 Chinese Pharmaceutical CDMO Companies”, “2023 Industry Benchmarking Award Best Industrial Enterprise and Best Pharmaceutical Industry”, “20th place in the 2022 China Chemical Pharmaceutical Enterprise Top 100 List and 12th Chinese CXO Enterprise TOP20”; and won the “2023 National Intellectual Property Demonstration Enterprise” Many honors include “2023 National Excellent Case of Enterprise Integrity Construction Practice”, “Zhejiang Science and Technology Little Giant Enterprise”, and “Second Batch of Zhejiang Intellectual Property Demonstration Enterprises”.
Company Profile
Company Executives
- Name
- Position
- Salary
- fangmeng zhu
- Chairman, Directors, Nomination Committee Members, Chairman of the Strategy Committee, Member of the Remuneration and Assessment Committee, Audit Committee Member
- 2.40M
- xinliang xu
- Vice Chairman, Directors, Nomination Committee Members, Strategy Committee Member, Member of the Remuneration and Assessment Committee, Audit Committee Member
- 1.44M
- wencai xu
- Directors, Strategy Committee Member
- --
- tiangao hu
- Directors, Strategy Committee Member
- --
- weiguang pan
- Independent Directors, Audit Committee Member, Chairman of the Nomination Committee, Member of the Remuneration and Assessment Committee, Strategy Committee Member
- 88.20K
- juanping qian
- Independent Directors, Member of the Remuneration and Assessment Committee, Chairman of the Audit Committee, Strategy Committee Member, Nomination Committee Members
- 88.20K
- ling chen
- Independent Directors, Nomination Committee Members, Strategy Committee Member, Chairman of the Remuneration and Assessment Committee, Audit Committee Member
- 88.20K
- yuwang zhou
- Board Secretary, Deputy General Manager
- 633.60K
- jian guan
- Securities Affairs Representative
- --
- guoping li
- Chairman of the Supervisory Board, Auditors
- --
- xiangquan ge
- Auditors
- --
- chun he
- General Manager
- 903.60K
- lei cai
- Deputy General Manager
- 810.00K
- min jin
- Senior Deputy General Manager
- 903.60K
- jinhui zhang
- Chief Financial Officer
- 653.60K
- wenbin nie
- Employee Supervisors
- 350.00K
Analysis
Price Target
No Data
No Data